Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

RSS icon
Withings Body Scan Connected Health Station FDA cleared

FDA clears new smart scale capable of detecting AFib, other cardiovascular issues

The Body Scan Connected Health Station includes a high-strength glass platform with four weight sensors and 14 ITO electrodes and a retractable handle with four stainless steel electrodes.

cardiologist doctor physician patient black diverse hypertension

Weight loss drug semaglutide linked to multiple benefits for heart failure patients

Researchers think their findings, which were presented at ESC Congress 2023 and published in the New England Journal of Medicine, could "change the nature of the conversation about the role of obesity in HFpEF."

amsterdam the netherlands

ESC Congress 2023: 4 key sessions scheduled for world’s largest gathering of cardiology professionals

The four-day event in Amsterdam officially begins on Friday, Aug. 25. Read our sneak preview of some of the conference's key sessions. 

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

FDA panel votes not to endorse Medtronic renal denervation system

The vote was close, initially ending with a tie, but the panel ultimately decided there were too many questions related to the device's long-term benefits for patients with uncontrolled hypertension.

Recor Medical's Paradise Ultrasound Renal Denervation System

FDA panel votes in favor of Recor Medical renal denervation system

A few members of the panel did question the device's efficacy and long-term durability. The FDA will now use these findings to make its final decision related to the system's approval. 

doctor with overweight patient who may be treated with TAVR or surgery

Weight loss drug semaglutide could boost heart health of up to 93M patients in US alone

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

Hari Naidu, MD, explains that inconsistent diagnostic imaging and how it is reported has likely led to a major underdiagnosis of HCM. #ASE #ASE2023 #HCM

Why hypertrophic cardiomyopathy may be widely underdiagnosed

One expert believes the lack of standardization for how diagnostic imaging in conducted and reported has led to a major underdiagnosis of HCM.

Displaying 153 - 160 of 962
Design by Adaptive Theme